A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries

References

• World Health Organisation. 2014 [cited 2014 Nov 13]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
   Google Scholar
• World Health Organisation. 2016 [cited 2016 Sep 28]. Available from: http://www.who.int/influenza/vaccines/use/en/
   Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
   PubMed Web of Science ®Google Scholar
• Apostolico Jde S, Lunardelli VA, Coirada FC, et al. Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016;2016:1459394.
   PubMed Web of Science ®Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51–57.
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–777.
   PubMedGoogle Scholar
• Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15(8):967–976.
   PubMed Web of Science ®Google Scholar
• Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085–1094.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. 2016 [cited 2016 Oct 19]. Available from: https://www.medicines.org.uk/emc/medicine/6207
   Google Scholar
• World Health Organisation. 2016 [cited 2016 Sep 28]. Available from: http://www.who.int/influenza/vaccines/virus/en/
   Google Scholar
• World Health Organisation. 2005 [cited 2016 Sep 28]. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/ANNEX%203%20InfluenzaP99-134.pdf?ua=1
   Google Scholar
• Van Der Vliet D, Pepin S, Lambert M, et al. Similar immunogenicity and safety of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum Vaccin Immunother. 2010;6(10):823–828.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. 2016 [cited 2016 Sep 28]. Available from: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/
   Google Scholar
• World Health Organisation. 2012 [cited 2016 Sep 28]. Available from: http://www.who.int/immunization_standards/vaccine_quality/pq_system/en/index.html
   Google Scholar
• Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–1930.
   PubMed Web of Science ®Google Scholar
• Kobbe R. The ESPID/ESWI Joint Symposium – a strong vote for universal influenza vaccination in children in Europe. Vaccine. 2015;33(49):6967–6969.
   PubMed Web of Science ®Google Scholar
• Cowling BJ, Ng S, Ma ES, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis. 2010;51(12):1370–1379.
   PubMed Web of Science ®Google Scholar
• Cowling BJ, Ng S, Ma ESK, et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis. 2012;55(5):695–702.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011;128(2):e276–e289.
   PubMed Web of Science ®Google Scholar
• Langley JM, Vanderkooi OG, Garfield HA, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc. 2012;1(1):55–63.
   PubMedGoogle Scholar
• Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485–2492.
   PubMed Web of Science ®Google Scholar
• Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine. 2011;29(47):8696–8704.
   PubMed Web of Science ®Google Scholar
• Han SB, Rhim JW, Shin HJ, et al. Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: double-blind, randomized, active-controlled multicenter phase III clinical trial. Hum Vaccin Immunother. 2015;11(5):1094–1101.
   PubMed Web of Science ®Google Scholar
• Li-Kim-Moy JP, Yin JK, Heron L, et al. Influenza vaccine efficacy in young children attending childcare: a randomised controlled trial. J Paediatr Child Health. 2017;53(1):47–54.
   PubMed Web of Science ®Google Scholar
• Pepin S, Szymanski H, Rochin Kobashi IA, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: a phase III randomized controlled study. Hum Vaccin Immunother. 2016;12(12):3072–3078.
   PubMed Web of Science ®Google Scholar
• Jianping H, Xin F, Changshun L, et al. Assessment of effectiveness of Vaxigrip. Vaccine. 1999;17(Suppl 1):S57–S58.
   PubMedGoogle Scholar
• Kim YK, Eun BW, Kim NH, et al. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6–35 months. Scand J Infect Dis. 2013;45(6):460–468.
   PubMed Web of Science ®Google Scholar
• Gonzalez M, Pirez MC, Ward E, et al. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child. 2000;83(6):488–491.
   PubMed Web of Science ®Google Scholar
• Lina B, Fletcher MA, Valette M, et al. A TritonX-100-split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European community for immunogenicity, in children, adults and the elderly. Biologicals. 2000;28(2):95–103.
   PubMed Web of Science ®Google Scholar
• Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011;11(1):23–29.
   PubMed Web of Science ®Google Scholar
• Loeb M, Ml R, Manning V, et al. Live attenuated versus inactivated influenza vaccine in Hutterite children: a cluster randomized blinded trial. Ann Intern Med. 2016;165(9):617–624.
   PubMed Web of Science ®Google Scholar
• Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. Jama. 2010;303(10):943–950.
   PubMed Web of Science ®Google Scholar
• Yin JK, Lahra MM, Iskander M, et al. Pilot study of influenza vaccine effectiveness in urban Australian children attending childcare. J Paediatr Child Health. 2011;47(12):857–862.
   PubMed Web of Science ®Google Scholar
• Beran J, Prymula R, Chlíbek R, et al. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (Vaxigrip and Fluarix) in the season 1996–1997. Cent Eur J Public Health. 1998;6(4):269–273.
   PubMedGoogle Scholar
• Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485–2492.
   PubMed Web of Science ®Google Scholar
• De Bruijn IA, Nauta J, Cramer WCM, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine. 2005;23:S39–S49.
   PubMed Web of Science ®Google Scholar
• Pépin S, Donazzolo Y, Jambrecina A, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31(47):5572–5578.
   PubMed Web of Science ®Google Scholar
• At’kov OY, Azarov AV, Zhukov DA, et al. Influenza vaccination in healthy working adults in Russia: observational study of effectiveness and return on investment for the employer. Appl Health Econ Health Policy. 2011;9(2):89–99.
   PubMedGoogle Scholar
• Liu YH, Huang LM, Jd W. Reduction of acute respiratory illness (ARI) due to a voluntary workplace influenza vaccination program: who are more likely to get the benefit? J Occup Health. 2004;46(6):455–460.
   PubMed Web of Science ®Google Scholar
• Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med. 2002;73(9):876–880.
   PubMedGoogle Scholar
• Morales A, Martinez MM, Tasset-Tisseau A, et al. Costs and benefits of influenza vaccination and work productivity in a Colombian company from the employer’s perspective. Value Health. 2004;7(4):433–441.
   PubMed Web of Science ®Google Scholar
• Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine. 1999;17(Suppl 3):S81–S87.
   PubMed Web of Science ®Google Scholar
• Mustafa AN, Gessner BD, Ismail R, et al. A case-control study of influenza vaccine effectiveness among Malaysian pilgrims attending the Haj in Saudi Arabia. Int J Infect Dis. 2003;7(3):210–214.
   PubMedGoogle Scholar
• Qureshi H, Gessner BD, Leboulleux D, et al. The incidence of vaccine preventable influenza-like illness and medication use among Pakistani pilgrims to the Haj in Saudi Arabia. Vaccine. 2000;18(26):2956–2962.
   PubMed Web of Science ®Google Scholar
• Gautret P, Steffen R. Communicable diseases as health risks at mass gatherings other than Hajj: what is the evidence? Int J Infect Dis. 2016;47:46–52.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. 2003;289(2):179–186.
   PubMed Web of Science ®Google Scholar
• Brydak LB, Machala M, Myśliwska J, et al. Immune response to influenza vaccination in an elderly population. J Clin Immunol. 2003;23(3):214–222.
   PubMed Web of Science ®Google Scholar
• Hui SL, Chu LW, Peiris JSM, et al. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine. 2006;24(25):5371–5380.
   PubMed Web of Science ®Google Scholar
• Praditsuwan R, Assantachai P, Wasi C, et al. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai. 2005;88(2):256–264.
   PubMedGoogle Scholar
• Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine. 2003;21(11–12):1268–1274.
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine. 2001;19(25–26):3472–3475.
   PubMed Web of Science ®Google Scholar
• Boge T, Remigy M, Vaudaine S, et al. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine. 2009;27(41):5677–5684.
   PubMed Web of Science ®Google Scholar
• Muszkat M, Greenbaum E, Ben-Yehuda A, et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 2003;21(11–12):1180–1186.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine. 2010;28(23):3929–3935.
   PubMed Web of Science ®Google Scholar
• Plasai V, Lertmaharit S, Viputsiri OA, et al. Influenza vaccination among the elderly in Bangkok. Southeast Asian J Trop Med Public Health. 2006;37(Suppl 3):140–144.
   PubMedGoogle Scholar
• Isahak I, Mahayiddin AA, Ismail R. Effectiveness of influenza vaccination in prevention of influenza-like illness among inhabitants of old folk homes. Southeast Asian J Trop Med Public Health. 2007;38(5):841–848.
   PubMedGoogle Scholar
• Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine. 2007;25(7):1196–1203.
   PubMed Web of Science ®Google Scholar
• Wang CS, Wang ST, Lai CT, et al. Reducing major cause-specific hospitalization rates and shortening hospital stays after influenza vaccination. Clin Infect Dis. 2004;39(11):1604–1610.
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Burtseva E, Yu H, et al. Influenza epidemiology and influenza vaccine effectiveness during the 2014–2015 season: annual report from the Global Influenza Hospital Surveillance Network. BMC Public Health. 2016;16(Suppl 1):757.
   PubMed Web of Science ®Google Scholar
• ECDC. 2016 [cited 2016 Sep 29]. Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/Documents/aer-seasonal_influenza-2016.pdf
   Google Scholar
• Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009;27(37):5043–5053.
   PubMed Web of Science ®Google Scholar
• Preaud E, Durand L, Macabeo B, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813.
   PubMed Web of Science ®Google Scholar
• Sa M, Cl C, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371(10):918–931.
   PubMed Web of Science ®Google Scholar
• Mutsaerts E, Madhi SA, Cutland CL, et al. Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Rev Vaccines. 2016;15(8):1055–1062.
   PubMed Web of Science ®Google Scholar
• Blanchard-Rohner G, Meier S, Bel M, et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn. Pediatr Infect Dis J. 2013;32(12):1374–1380.
   PubMed Web of Science ®Google Scholar
• Omer SB, Richards JL, Madhi SA, et al. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: methods and expectations. Vaccine. 2015;33(32):3801–3812.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Tielsch J, Katz J, et al. Evaluation of year-round maternal influenza immunization in tropical SE Asia: a placebo-controlled randomized trial (Abstract 1898). In: IDWeek. San Diago (CA); 2015.
   Google Scholar
• Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis. 2016;16(9):1026–1035.
   PubMed Web of Science ®Google Scholar
• Phadke VK, Omer SB. Maternal vaccination for the prevention of influenza: current status and hopes for the future. Expert Rev Vaccines. 2016;15(10):1255–1280.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2016 [cited 2016 Sep 28]. Available from: http://drug.fda.moph.go.th/zone_search/files/2C_16_48_N_VAXIGRIP.pdf
   Google Scholar
• Chan SSW. Does vaccinating ED health care workers against influenza reduce sickness absenteeism? Am J Emerg Med. 2007;25(7):808–811.
   PubMed Web of Science ®Google Scholar
• Regan AK, Tracey L, Blyth CC, et al. A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women. BMC Pregnancy Childbirth. 2015;15:1.
   PubMed Web of Science ®Google Scholar
• Sa M, Dittmer S, Kuwanda L, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. Aids. 2013;27(3):369–379.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Srirompotong U, Newman RW, et al. Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine. 2011;29(16):3055–3060.
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Zangari P, Cotugno N, et al. Antibody but not memory B-cell responses are tuned-down in vertically HIV-1 infected children and young individuals being vaccinated yearly against influenza. Vaccine. 2014;32(6):657–663.
   PubMed Web of Science ®Google Scholar
• Montoya CJ, Toro MF, Aguirre C, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz. 2007;102(4):501–508.
   PubMed Web of Science ®Google Scholar
• Banic S, Koren S, Tomazic J, et al. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol. 2001;45(1):39–44.
   PubMed Web of Science ®Google Scholar
• Rasoolinejad M, Jafari S, Montazeri M, et al. Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus. Acta Med Iran. 2013;51(3):148–152.
   PubMedGoogle Scholar
• Chisholm JC, Devine T, Charlett A, et al. Response to influenza immunisation during treatment for cancer. Arch Dis Child. 2001;84(6):496–500.
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Lu MY, Kao CL, et al. Response to influenza vaccine in children with leukemia undergoing chemotherapy. J Formos Med Assoc. 2002;101(10):700–704.
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Frias MN, Garcia-Leon ML, et al. Humoral and cellular immune responses to influenza vaccination in children with cancer receiving chemotherapy. Oncology Letters. 2012;4(2):329–333.
   PubMed Web of Science ®Google Scholar
• Loulergue P, Alexandre J, Iurisci I, et al. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br J Cancer. 2011;104(11):1670–1674.
   PubMed Web of Science ®Google Scholar
• Sasson M, Mandelboim M, Shvartzman P. Influenza vaccination for terminally ill cancer patients receiving palliative care: a preliminary report. J Pain Symptom Manage. 2011;41(2):485–490.
   PubMed Web of Science ®Google Scholar
• Antonen JA, Hannula PM, Pyhala R, et al. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000;86(1):56–61.
   PubMed Web of Science ®Google Scholar
• Antonen JA, Pyhala R, Hannula PM, et al. Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol Dial Transplant. 2003;18(4):777–781.
   PubMed Web of Science ®Google Scholar
• Cavdar C, Sayan M, Sifil A, et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003;37(1):71–76.
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Cagigi A, Santilli V, et al. B-sides serologic markers of immunogenicity in kidney transplanted patients: report from 2012–2013 flu vaccination experience. Transplantation. 2014;98(3):259–266.
   PubMed Web of Science ®Google Scholar
• Salles MJ, Sens YA, Boas LS, et al. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant. 2010;24(1):E17–E23.
   PubMed Web of Science ®Google Scholar
• Hojsak I, Avitzur Y, Mor E, et al. Antibody response to influenza vaccine in pediatric liver transplant recipients. Pediatr Infect Dis J. 2011;30(6):491–494.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552–558.
   PubMed Web of Science ®Google Scholar
• Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730–733.
   PubMed Web of Science ®Google Scholar
• Wongsurakiat P, Maranetra KN, Gulprasutdilog P, et al. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. Respirology. 2004;9(4):550–556.
   PubMed Web of Science ®Google Scholar
• Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125(6):2011–2020.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52(1):128–137.
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Gavazzi G, Richard P, et al. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax®) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip®) to adults aged ≥60 years: an open-label, randomised trial. Vaccine. 2013;31(11):1496–1502.
   PubMed Web of Science ®Google Scholar
• Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51(9):1007–1016.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2016 [cited 2016 Sep 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf
   Google Scholar
• Delore V, Salamand C, Marsh G, et al. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine. 2006;24(10):1586–1592.
   PubMed Web of Science ®Google Scholar
• Alguacil Ramos AM, Lluch Rodrigo JA, Portero Alonso A, et al. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009–2010 and 2010–2011. Valencian community, Spain]. Rev Esp Salud Publica. 2012;86(3):241–251.
   PubMed Web of Science ®Google Scholar
• Alguacil-Ramos AM, Garrigues-Pelufo TM, Muelas-Tirado J, et al. [Safety of influenza vaccines in risk groups: analysis of adverse events following immunization reported in Valencian Community from 2005 to 2011]. Rev Esp Quimioter. 2015;28(4):193–199.
   PubMed Web of Science ®Google Scholar
• Lafleche J, Ahmadipour N, Kim S, et al. Surveillance of adverse events following immunization (AEFI) with trivalent inactivated influenza vaccines in Canada, 2000–2009. Can J Infect Dis Med Microbiol. 2010;21(4):213.
   Google Scholar
• Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010. Vaccine. 2010;28(45):7248–7255.
   PubMed Web of Science ®Google Scholar
• Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114–2120.
   PubMed Web of Science ®Google Scholar
• Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: vaccine Adverse Event Reporting System (VAERS)–United States, 1991–2001. MMWR Surveill Summ. 2003;52(1):1–24.
   PubMedGoogle Scholar
• Harris TM, Wong K, Fediurek J, et al. Assessment of sex-specific differences in adverse event following imunization reporting in Ontario, Canada (Abstract no. 332). Pharmacoepidemiol Drug Saf. 2015;24:186.
   Web of Science ®Google Scholar
• European Medicines Agency (Pharmacovigilance Risk Assessment Committee). 2014 [cited 2016 Oct 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf
   Google Scholar
• European Medicines Agency (Pharmacovigilance Risk Assessment Committee). 2015 [cited 2016 Oct 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2015/03/WC500184892.pdf
   Google Scholar
• Houdouin V, Lavis N, Meyzer C, et al. Safety of the Northern Hemisphere 2014/2015 formulation of the inactivated split-virion intramuscular trivalent influenza vaccine. Vaccine Reports. 2016;6:1–7.
   Google Scholar
• Spila-Alegiani S, Salmaso S, Rota MC, et al. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination. Vaccine. 1999;17(15–16):1898–1904.
   PubMed Web of Science ®Google Scholar
• Morales A, Arias Salazar J, Salazar Y, et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia. Medicina (B Aires). 2003;63(3):197–204.
   PubMed Web of Science ®Google Scholar
• Talbot HK, Nian H, Zhu Y, et al. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis. 2015;60(8):1170–1175.
   PubMed Web of Science ®Google Scholar
• Castilla J, Navascues A, Fernandez-Alonso M, et al. Effectiveness of subunit influenza vaccination in the 2014–2015 season and residual effect of split vaccination in previous seasons. Vaccine. 2016;34(11):1350–1357.
   PubMed Web of Science ®Google Scholar
• Centres for Disease Control and Prevention. 2016 [cited 2016 Sep 29]. Available from: http://www.cdc.gov/flu/pdf/professionals/vaccination/vaccine-effectiveness-table.pdf
   Google Scholar
• Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis. 2012;54(10):1427–1436.
   PubMed Web of Science ®Google Scholar
• Owusu JT, Prapasiri P, Ditsungnoen D, et al. Seasonal influenza vaccine coverage among high-risk populations in Thailand, 2010–2012. Vaccine. 2015;33(5):742–747.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses. 2009;3(1):37–49.
   PubMed Web of Science ®Google Scholar
• Yang J, Atkins KE, Feng L, et al. Seasonal influenza vaccination in China: landscape of diverse regional reimbursement policy, and budget impact analysis. Vaccine. 2016;34(47):5724–5735.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Shay DK, Zhou H, et al. Estimates of deaths associated with seasonal influenza — United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–1062.
   PubMedGoogle Scholar
• Centres for Disease Control and Prevention. 2016 [cited 2016 Sep 29]. Available from: http://www.cdc.gov/flu/fluvaxview/coverage-1516estimates.htm
   Google Scholar
• European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in Europe – overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons. Stockholm: ECDC; 2016.
   Google Scholar
• Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322–1332.
   PubMed Web of Science ®Google Scholar
• Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine. 2002;20(19–20):2562–2578.
   PubMed Web of Science ®Google Scholar
• Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15(3):369–390.
   PubMed Web of Science ®Google Scholar
• Black S. Recognizing the importance of vaccine confidence. EBioMedicine. 2016;12:28–29.
   PubMed Web of Science ®Google Scholar
• Larson HJ, De Figueiredo A, Xiahong Z, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295–301.
   PubMed Web of Science ®Google Scholar
• Palache A, Oriol-Mathieu V, Fino M, et al. Influenza Vaccine Supply task force. Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. Vaccine. 2015;33(42):5598–5605.
   PubMed Web of Science ®Google Scholar
• Pan America Health Organization. 2016 [cited 2016 Sep 29]. Available from: http://ais.paho.org/imm/InfluenzaCoverageMap.asp
   Google Scholar
• Centers for Disease Control and Prevention. 2016 [cited 2016 Oct 2]. Available from: http://www.cdc.gov/flu/fluvaxview/coverage-1415estimates.htm
   Google Scholar
• World Health Assembly. 2003 [cited 2016 Sep 29]. Available from: http://apps.who.int/gb/archive/pdf_files/WHA56/ea56r19.pdf
   Google Scholar
• Council of the European Union. 2009 [cited 2011 Jun 11]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
   Google Scholar
• 2020. HP. 2016 [cited 2016 Oct 2]. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives
   Google Scholar
• Australian Government Department of Health. 2015 [cited 2016 Sep 29]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/5BAB80E0DC5A47DBCA257EE400130AD3/$File/Australian-Influenza-Surveillance-Report.pdf
   Google Scholar
• Jennings Z, Carter I, McPhie K, et al. Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. Euro Surveill. 2015;20:31.
   PubMedGoogle Scholar
• The Hon Sussan Ley MP. 2015 [cited 2016 Sep 29]. Available from: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2015-ley133.htm?OpenDocument&yr=2015&mth=11
   Google Scholar
• European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, July 2016. Stockholm: ECDC; 2016.
   Google Scholar
• Agencies HoM. 2016 [cited 2016 Oct 19]. Available from: http://mri.medagencies.org/Human/Product/Details/47992
   Google Scholar